Steven M. Greenberg, MD, PhD, FAHA, Chair; Wendy C. Ziai, MD, MPH, FAHA, Vice Chair;
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …

Intracerebral haemorrhage (ICH) is a devastating condition associated with high mortality
and substantial residual disability among survivors. Effective treatments for the acute stages …

Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative
review aimed to highlight the current evidence and recommendations of antiplatelet therapy …

Objective Antiplatelet medications are increasingly being used for primary and secondary
prevention of ischemic attacks owing to the increasing prevalence of ischemic stroke …

Alzheimer's disease (AD) and cardiovascular disease (CVD) are strongly associated. Both
are multifactorial disorders with long asymptomatic phases and similar risk factors. Indeed …

Stroke is the second leading cause of death and disability worldwide, with a
disproportionate burden on low-and middle-income countries. Critical elements of guideline …

Background Patients with non-traumatic intracerebral haemorrhage have a substantial risk
of major adverse cardiovascular and cerebrovascular events, including ischaemic stroke …

Objectives Evidence of the optimal antiplatelet therapy for elderly patients who had a stroke
is limited, especially those elder than 80 years. This study aimed to explore the efficacy and …

Background: The appropriate timing of resuming antithrombotic therapy after intracerebral
hemorrhage (ICH) remains unclear. The aim of this study was to compare the risks of major …

Antithrombotic therapy is a key element of secondary prevention in patients who have had
an ischaemic stroke or transient ischaemic attack. However, its use in clinical practice is not …